Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD seeks views on cutting red tape
red tape
An ATC is required for clinical field trials of unauthorised veterinary medicines administered to patients in order to treat or prevent disease.
Proposals to change ATC approach could save over £200k

In a bid to cut costs and red tape, the Veterinary Medicines Directorate (VMD) is reviewing its approach to issuing animal test certificates (ATCs), which permit the use of unauthorised veterinary medicines in clinical field trials.

Responding to concerns raised during the Red Tape Challenge 2013, the VMD is proposing to change the way it issues ATCs for those intending to work under Recognised Veterinary Practice. It estimates the changes could save the industry more than £200,000 per year.

The changes would allow blood samples to be taken when a medicine is administered and at intervals throughout the trial, assuming this is being done for the benefit of the enrolled animal - i.e. the animal is being treated and the blood samples support that treatment.

Currently, an ATC is required for clinical field trials of unauthorised veterinary medicines administered to patients in order to treat or prevent disease, in accordance with Recognised Veterinary Practice.

The certificate permits the use of the medicine, allows it to be procured and supplied and also allows produce from treated animals to enter the food chain. The aim is to safeguard animals enrolled in the trial, those administering the treatment (i.e. the vet), those eating food products from treated animals and the environment.

For experimental studies (not carried out under Recognised Veterinary Practice), a licence is required from the Home Office under the Animals (Scientific Procedures) Act 1986 (A(SP)A). This will not change under the new proposals.

Under the current system, the VMD only considers a study to be a clinical trial carried out under Recognised Veterinary Practice if just one blood sample is taken. If more than one sample is taken, it is considered experimental and an A(SP)A licence is required. When in doubt, the VMD seeks the advice of the RCVS.

From 2009-2012, the VMD issued 76 ATCs for 31 different companies. It is anticipated that the number of applications would rise if the proposed changes go through.

To take part in the consultation, which runs until April 24, submit your views to d.burge@vmd.defra.gsi.gov.uk, or write to: Denise Burge, Veterinary Medicines Directorate, Woodham Lane, New Haw, Surrey, KT15 3LS. For more information see https://consult.defra.gov.uk/vmd/review-of-approach-to-issuing-an-atc

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.